Immune checkpoint blockade (ICB) therapy has recently shown promise in treating several
malignancies. However, only a limited number of patients respond to this treatment, partially …

Preclinical models of cancer have long been paramount to understanding tumor
development and advancing the treatment of cancer. Creating preclinical models that mimic …

Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain
limited. This raises the possibility that standard of care treatments delivered in concert may …

Locally advanced cancers remain therapeutically challenging to eradicate. The most
successful treatments continue to combine decades old non-targeted chemotherapies with …

Immune checkpoint inhibitors (ICIs) effectively treat lung adenocarcinoma (LUAD) with fewer
side effects. However, for LUAD patients, the lack of predictive markers for ICIs makes their …

Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 …

Cotransins target the Sec61 translocon and inhibit the biogenesis of an undefined subset of
secretory and membrane proteins. Remarkably, cotransin inhibition depends on the unique …

Simple Summary PI3K/Akt pathway has an impressive story as tumor marker. PI3K-
dependent solid tumors have been studied for several years in order to inhibit the pathway …

N6-methyladenosine (m6A) is the most common mRNA modification and it plays a critical
role in tumor progression, prognoses and therapeutic response. In recent years, more and …

Acinar cells are the principal secretory units of multiple exocrine organs. A single-cell,
layered, lumenized acinus forms from a large cohort of epithelial progenitors that must …